* UNKNOWN * | MPSJCA | JCA10.0.1465/W Unicode | cn-2015-00156g.3d (R3.6.i9 HF02:4386 | 2.0 alpha 39) 2015/05/14 15:05:00 | PROD-JCAVA | rq_4839118 |
7/02/2015 13:33:37 | 13 | JCA-DEFAULT
Research Article
pubs.acs.org/chemneuro
Investigation of Neuropathogenesis in HIV‑1 Clade B and C Infection
2 Associated with IL-33 and ST2 Regulation
1
Adriana Yndart,† Ajeet Kaushik,† Marisela Agudelo,† Andrea Raymond,† Venkata S. Atluri,†
‡
,†
4 Shailendra K Saxena, and Madhavan Nair*
3
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
†
Center of Personalized Nanomedicine, Institute of Neuropharmacology, Department of Immunology, Herbert Wertheim College of
Medicine, Florida International University, Miami, Florida 33199, United States
‡
Centre for Cellular and Molecular Biology (CSIR), Hyderabad 500007, Andhra Pradesh, India
ABSTRACT: In present research work, for the first time, we demonstrate that neuropathogenesis in HIV-1 clade B and C infection is associated with IL-33 and ST2
dysregulation, that is, implication toward neuropathogenesis. It is known that
neuropathogenesis of HIV infected individuals is clade dependent. Proinflammatory
cytokines and related receptors play a significant role in the complex regulatory
mechanisms of neuropathogenesis in HIV-1 infection. Among them, IL-33 is an
inflammatory cytokine expressed in the central nervous system (CNS) and activates
microglia cells and may affect neuroimmune inflammatory processes involved in
HIV neuropathogenesis. Beside this, IL-33 receptor (ST2) plays a role in
neuroinflammatory processes through the modulation of the biological action of
IL-33. quantitative real time PCR (qRT-PCR), ELISA, Western blot (WB), and flow
cytometry experiments were performed to elucidate the role of IL-33/ST2 in HIV
neuropathogenesis in CNS cells. Apoptosis and mechanisms of IL-33 in neuronal cells
were studied using caspase-3 assay and RT-PCR. Results of the studies suggest that the
infection in CNS cells with HIV-1 clade B resulted in higher levels of IL-33/ST2L expression compared to HIV-1 clade C
infection. Furthermore, higher concentrations of IL-33 were associated with a decrease in myocyte enhancer factor 2C (MEF2C)
expression, a transcription factor that regulates synaptic function, and an increase in apoptosis, NOD2, and SLC11A1 in clade B
infection. This led to neuroinflammation which dysregulates synaptic function and apoptosis. These parameters are common in
neuroAIDS provoked by HIV infection.
KEYWORDS: Neuroinflammation, synaptic plasticity, neuroAIDS, HIV-1, clade B, clade C, IL-33, ST2
M
mechanisms of the differential neuro-effects between clades.
The regulation of proinflammatory cytokines and their
receptors played a significant role in the complex regulatory
mechanisms of HIV-1 neuropathogenesis.1 Among cytokines,
interleukin-33 (IL-33), a member of the IL-1 family,7,8 plays a
major role in a wide range of inflammatory responses.8−11 IL-33
has been shown to induce T helper type 2 responses by
activating NF-κB and MAP kinases via binding to its receptor
ST2, which is a member of the toll-like receptor superfamily.
Studies confirm that IL-33 and ST2 were found to be expressed
in the central nervous system (CNS). Wherein, IL-33 activates
microglia cells and increases M-CSF levels8,11−13 to act as a
potent mitogen facilitating increased phagocytosis.13 The
elevated IL-33 has been observed in various neurological
disorders,13,14 and no studies have been reported related to the
role of IL-33/ST2 in HIV-I infection with clades B and C.
Recently, our group demonstrated that HIV-1 clade B is a
major suppressor of synaptic plasticity genes compared to clade
C.15 Studies have also reported a relationship between inflammatory conditions and disparities of synaptic plasticity.16−21
anifestations of neuroAIDS between HIV-1 clades are
differentially regulated. HIV viruses responsible for the
pandemics belong to lineage M and are subdivided into
10 clades (from A to K). Clades B and C are part of that HIV
subdivision, and clade classification is mainly based on nucleotide sequences derived from multiple subgenomic regions (gag,
pol, and env). Interclades, env is the most variable gene
encountered which is about 20−30%, while pol regions are less
divergent. The env gene, which encodes the envelope surface
glycoprotein 120 (gp120) and transmembrane glycoprotein
41 (gp41), can exhibit 35% amino acid diversity between
subtypes with most of the genetic variation occurring in gp120.
In addition, significant differences have been reported based on
the nonstructural regulatory TAT protein among clades.1,2
In the Western world, clade B is the predominant HIV-1
subtype. An elevated percentage of HIV Associated Neurocognitive Disorders (HAND) has been found associated with
clade B, while in regions where clade C is prevalent, a low or
mild incidence of HAND is reported.3−5 Many reports suggest
lower neuropathogenesis in clade C infection than that of clade
B infections.7,8 Thus, studying different factors to understand
clade-specific effects on neuropathogenicity is crucial and worth
exploring.6 A clear explanation is not proposed yet to elucidate
© XXXX American Chemical Society
Received: June 1, 2015
A
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
ACS Chemical Neuroscience
71
72
73
74
75
76
77
78
79
Research Article
SKNMC (Figures 2 and 3). CNS cells were infected with HIV
and harvested 7 days post infection. RNA was extracted, and
the expression of IL-33 and ST2 was examined. Clade B
infection upregulated both genes, while the induction of IL-33
(Figure 2A, E) and ST2 (Figure Figure 3A, E) in clade C
infected cells was less significant.
In order to see whether increased gene expression truly correlated with elevated protein levels, the effects of HIV-1 infection on the secretion of IL-33 and ST2 were checked by ELISA,
and intracellular expression was investigated using Western blot
(WB) and flow cytometry. Outcomes showed the secreted
IL-33 production was significantly higher in HIV infected
cultures compared to noninfected controls (Figure 2B, F). Clade B
significantly increased the secretion of IL-33 (Figure 2B, F) compared to clade C; nevertheless, no significant differences were found
for the soluble receptor ST2, in both CNS cell lines (Figure 3B, F).
The intracellular IL-33 (Figure 2C, D, G, H) and ST2 (Figure 3C,
D, G, H) proteins were differentially upregulated in HA and
SKNMC with respect to both clades as compared with uninfected
controls. Statistical differences were found between clades when
they were analyzed by WB (Figure 2C, G, and Figure 3C, G) and
flow cytometry (Figure 2D, H, and Figure 3D, H). Further, the flow
cytometry results show significant increases in IL-33 and ST2 in
clade B infected cells; however, in clade C infected cells, nonsignificant levels of IL-33 and ST2 upregulation were observed
compared to controls. Results reveal that no doublets appeared
during flow cytometry experiments.
IL-33 Induction Correlates with a Decrease in
Synaptic Plasticity As Measured by MEF2C Expression.
Neuronal plasticity has been shown to be modulated by
inflammation, and MEF2C has been correlated with synapse
regulation, neuronal survival, and differentiation.26,27 Given the
role of MEF2C, we assessed the impact of IL-33 on MEF2C
expression using RT-PCR (Figure 4A) and flow cytometry
(Figure 4B). To determine whether IL-33 directly modulated
MEF2C expression, SKNMC cells were treated with various
concentrations of IL-33 (120, 240, and 480 pg/mL) selected
from the ELISA results after HIV-1 infection (Figure 2F). Our
data indicates that IL-33 and MEF2C expression were inversely
proportional (Figure 4A, B). Further, a significant downregulation of MEF2C gene and protein were obtained after
clade B infection (Figure 4C, D). During experiments no
doublets were visible.
IL-33 Contributes to HIV-Induced Apoptosis in CNS
Cells. It is well-known that HIV infection promotes inflammation and apoptosis; therefore, we wanted to determine the
potential role of inflammatory conditions induced by IL-33 in
this process. To determine whether IL-33 promotes apoptosis
in HIV-infected neuronal cells, we tested the caspase-3 levels in
SKNMC cells infected with HIV clade B or C. The level of
apoptosis as measured by caspase-3 activity was significantly
higher after HIV-1 infection (Figure 5). Cells infected with
HIV-1 clade B showed significantly higher apoptosis than cells
infected with clade C. Similar results were observed for IL-33
treatment of SKNMC where an increased in IL-33 levels
resulted in elevated SKNMC apoptosis suggesting a role for
IL-33 in the induction of neuropathogenic mechanisms. Taken
together, these results suggest that the clade B infection is more
neuropathogenic to neuronal cells than clade C.
IL-33 Induces Immune Response Activation in CNS
Cells. Response to the treatment of 2 ng of IL-33 by SKNMC
was analyzed using human innate and adaptive immune response RT PCR array. Six genes (CSF2, MX1, NOD2, RAG1,
The transcription factor, myocyte enhancer factor 2 (MEF2), is
known to regulate a variety of synaptic functions, including
synapse weakening, maturation, and development.21,22 In particular, one of the isoforms involved in hippocampal synaptic
function is MEF2C, which has been correlated with synapse
regulation, neuronal survival, and differentiation.21,22 The
rationale and hypothesis related to neuropathegensis HIV-1
clade B and C infection associated with IL-33 and ST2 dysregulation are illustrated in Scheme 1.
Scheme 1. Rationale and Hypothesis Related to the
Neuropathogensis HIV-1 Clades B and C Infection
Associated with IL-33 and ST2 Dysfunction
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
In this work, for the first time, we investigate the modulation
of IL-33/ST2, with HIV-1 clade B and C infection in CNS cells.
Outcomes suggest that increment of IL-33, mainly, by HIV-1
clade B is related with differential manifestations inneuroAIDS
through the modulation of MEF2C expression, induction of
neuronal apoptosis, and mechanisms of action of IL-33 leading
to increased neuropathogenesis.4
RESULTS
Twofold HIV-1 Clade C Inoculum Yields Equivalent
Clade B Infectivity of HA and SKNMC. Lower infectivity
was achieved in HIV 1 clade C than in HIV-1 clade B infected
cultures. To compensate, we standardized the inoculum to
reach equivalent levels of infection. As measured using p24
ELISA, 200 ng of clade C and 100 ng of clade B produced
an equal amount of p24 in human astrocytes and SKNMC.
(Figure 1). All experiments were performed under the same
conditions. Equal levels of infection were checked for each
batch of experiment before proceeding with further gene and
protein analyzes. Infections did not affect significantly the
viability of the cells (data not shown).
IL-33 and ST2 Are Upregulated in HIV-1 Clade B
Infection. Epidemiological22−24 and in vitro studies1 have
reported differences in neuroAIDS and cytokines during HIV-1
clade B and C infection. In particular, recent reports have
shown a role for IL-33 in the immune response of cells in the
CNS.8,13,25 Therefore, we decided to compare the effects
of both clades on IL-33, and its receptor, ST2, in HA and
■
B
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
ACS Chemical Neuroscience
Research Article
Figure 1. HIV clade B and C infection of HA and SKNMC yield equal p24 levels after 7 days of infection. HA and SKNMC cells were infected
separately at different p24 starting concentration for HIV-1 B and C clades overnight with previous Polybrene activation. On day 7 postinfection, the
supernatants were collected and tested with p24 ELISA Zeptometrix (Cat#: NC9130878). Data represent the means ± standard error of three
independent experiments. All the data were analyzed using GraphPad Prism software. Comparisons between groups were performed using one-way
ANOVA and Tukey’s multiple comparison post test. Differences were considered significant at p ≤ 0.05.
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
SLC11A1, and TLR7) were found to be upregulated with
significant increment of NOD2 (nucleotide-binding oligomerization domain containing 2) and SLC11A1 (solute carrier
family 11 proton-coupled divalent metal ion transporters,
member 1), while three genes were downregulated (CXCR3,
TLR2, and TLR9). Data are shown in Table 2. The major
impacts were found in NOD2 (fold change = 6.63) and
SLC11A1 (fold change = 3.97) compared to control. Downregulated genes had no more than 3.0-fold change. TLR2 had
the highest downregulation with a fold change of 2.69 compared to control.
infection (Figure 2). Clade B significantly increased IL-33
compared to clade C (Figure 2B, F). Nevertheless, no
significant differences were found for the soluble receptor
ST2, in both CNS cell lines (Figure 3B, F). This can be
associated with an over production of secreted IL-33 that may
block soluble ST2 receptors.
Though, studies reported that the soluble form of the
receptor ST2 is generated and associated with IL-33. Also IL-33
blocks ST2-dependent signaling including the immunological
effects of IL-33.8,13,25 However, no significant levels of soluble
receptors were observed in our study. Beside this, the significant impact in IL-33 production and function were
observed. For example, MEF2C modulation and apoptosis,
leading us to conclude that secreted ST2 levels have no effects
on the inflammation induced by HIV clade B and C infection
(Figure 3B, F). Inflammatory conditions aggravate the effects
induced by HIV infection and our results have demonstrated
that clade B and C are differentially inducing IL-33 and ST2
(Figure 2 and 3). In our work, SKNMC cells were treated with
different IL-33 concentrations to explore the functional role of
IL-33 in synaptic plasticity. Since MEF2C has been correlated
with synaptic regulation, neuronal survival, and differentiation,26,27 MEF2C expression analysis was made after HIV
infection in the presence of increased levels of IL-33.
Findings of our research demonstrated a differential regulation on MEF2C when cells were infected using clades B and C.
Higher expression of MEF2C was observed in HIV-1 clade C
and lower in HIV-1 clade B infected cells. This can be related
with different HIV associated neurocognitive disorders as
reported earlier.1 Further, we reported clades B and C as having
differential effects on synaptic plasticity gene and spine density
on CNS cells.15
DISCUSSION
The present study established a relation between IL-33 and
ST2 dysfunction and HIV clade B and C infection. An upregulation of IL-33 produced by HIV-1 clade B infected
cells was observed in comparison to clade C, under identical
in vitro infection levels. These clade-specific responses can be
associated with neuropathogenesis increment,1,15,20 and other
inflammatory cytokines were upregulated with respect to clade
B than that of clade C.1,20 On the contrary, higher levels of ST2
and low levels of IL-33 were found in plasma samples of HIV
infected patients.28 However, other details of clade differences
and associated dependent factors, coinfections besides HIV,
and the use of ARV were not considered in presented work.
We focused only on in vitro neuropathogenesis in HIV clade
B and C infection, and clade-specific effects on IL-33 and ST2.
Obtained findings manifested an increment in the production
of IL-33 (Figure 2) and ST2 (Figure 3) in HIV infection on
comparing with controls. The upregulation of IL-33 was
consistently higher in HIV clade B infected astrocytes and
SKNMC, whereas it was lower in the case of HIV-1 clade C
■
C
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
ACS Chemical Neuroscience
233
234
235
236
237
Research Article
Cytokines have been associated with the impairment of
synaptic plasticity as in the case of IL-1, TNFα, IL-18, and IL-6.
Unfortunately, there are no reports elucidating the role of IL-33
and its receptor ST2 on synaptic plasticity. Our study showed a
role of IL-33 on synaptic plasticity modulation as indicated by
an inverse correlation of IL-33 and MEF2C (Figure 4). Doses
were selected according to the different concentrations
obtained in IL-33 ELISA in the cases of HIV 1B infection in
SK-N-MC cells. Surprisingly, dose response data demonstrated
that IL-33 and MEF2C are inversely correlated since at a lower
Figure 2. continued
D
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
238
239
240
241
242
ACS Chemical Neuroscience
Research Article
Figure 2. IL-33 expression is upregulated in HIV-1 clade B infection. HA and SKNMC cells were infected separately with HIV-1 B and C clades as
described in Methods. On day 7 postinfection, RNA was extracted and reverse transcribed followed by quantitative real time PCR for IL-33 gene
(A, E). Supernatants were used for ELISA (B, F), while cell lysates were used for Western blot (C, G). Cells were stained to determine IL-33 protein
expression by flow cytometry (H). Data represents the means ± standard error of three independent experiments. All the data were analyzed using
GraphPad Prism software. Comparisons between groups were performed using one-way ANOVA and Tukey’s multiple comparison post test.
Differences were considered significant at p ≤ 0.05.
E
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
ACS Chemical Neuroscience
243
244
245
246
247
Research Article
cytokine impacts negatively the synaptic plasticity transcriptional factor probably as a feedback mechanisms in response to
chronic inflammation.20,29−31 For instance, in the case of other
inflammatory cytokines such as TNFα, an upregulation of
AMPA receptors is produced at physiological levels of TNFα,
concentration of IL-33 (120 pg/mL) there was an increase in MEF2C
gene expression, while the higher dose of IL-33 (480 pg/mL)
produced a significant downregulation of MEF2C.20,29−31
We speculate that lower doses of IL-33 may exert a protective effect on synaptic plasticity and the accumulation of this
Figure 3. continued
F
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
248
249
250
251
252
ACS Chemical Neuroscience
Research Article
Figure 3. ST2L expression is upregulated in HIV-1 clade B infection. No differences were found in soluble ST2. HA and SKNMC cells were infected
separately with HIV-1 B and C clades as described in Methods. On day 7 postinfection, RNA was extracted and reverse transcribed followed by
quantitative real time PCR for ST2 gene (A, E). Supernatants were used for ELISA (B, F), while cell lysates were used for Western blot (C,G). Cells
were also stained to determine ST2 expression by flow cytometry. Data represents the means ± standard error of three independent experiments. All
the data were analyzed using GraphPad Prism software. Comparisons between groups were performed using one-way ANOVA and Tukey’s multiple
comparison post test. Differences were considered significant at p ≤ 0.05.
G
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
ACS Chemical Neuroscience
Research Article
Figure 4. IL-33 induction correlates with a decrease in synaptic plasticity as measured by MEF2C expression. SKNMC cells were treated with
different IL33 concentrations (120, 240, and 480 pg/mL) for 24 h. (A) RNA was extracted and reverse transcribed followed by quantitative real time
PCR for MEF2C gene. (B) Intracellular MEF2C was measured by flow cytometry. The histogram shows an overlay of total cells. The bar graph
represents the mean ± standard error of percent of mean fluorescence intensity. (C) SKNMC cells were infected with HIV-1 clades B and C. (D)
After 7 days of infection, cell lysates were used for RT-PCR and Western blot. The figure represents the gene expression. Data represents the means
± standard error of three independent experiments. All the data were analyzed using GraphPad Prism software. Comparisons between groups were
performed using one-way ANOVA and Tukey’s multiple comparison post test. Differences were considered significant at p ≤ 0.05.
H
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
ACS Chemical Neuroscience
Research Article
SKNMC cells were treated with human recombinant IL-33
for 7 days to investigate the role of other activated genes
involving in innate and adaptive immune response on the
effects observed after IL-33 treatment, and to elucidate the
mechanisms of IL-33 in neuronal cells (Tables 1 and 2). The
results showed an increment in the regulation of nucleotidebinding oligomerization domain (NOD2). NOD-like receptor
(NLR) signaling represents a major class of cytosolic pattern
recognition receptors (PRR) that, like their cell-surface toll-like
receptor counterparts, recognize a wide variety of pathogens
and immunogenic biological products. Activation of one of four
PRR family members initiates the formation of an inflammasome. These protein complexes in turn activate caspase-1,
leading to upregulation of the proinflammatory cytokines IL1B
and IL18 and pyroptosis, or caspase-1-dependent programmed
cell death.35
The activation of NOD2 was produced by treatment with the
higher concentrations of IL-33, which was observed during HIV
1 clade B infection, only. IL-33 may be considered as NOD2
agonist, inducing the activation of the inflammatory markers
c-Jun N terminal kinase, ERK1/2, and p38 MAPK, degradation
of inhibitor of kBα,35 and induction of NF-κB signaling
pathway and inflammatory cytokines.36 According to previous
work, HIV infection can upregulate the production and activity
of NF-κB, leading to an increment of proinflammatory
cytokines, including IL-33, which is considered a beneficial
environment to increase the HIV infection.37 This mechanism
may be related with the induction of clade specific neuroAIDS
manifestation.38
The solute carrier family, with 11 proton-coupled divalent
metal ion transporters (SLC11A1), was activated with higher
IL-33 concentration treatment in SKNMC with a fold change
of 3.97. An upregulation of SLC11A1 was reported on
treatment with toxins leading to the activation of mechanisms
that support host defense against pathogens including
activation of inflammatory responses.39 Transcriptional activation of SLC11A1 leads to apoptosis, in accordance with the
notion that genes that deplete the iron content of the cell
cytosol antagonize cell growth.40 The activation of SLC11A1
using IL-33 is related to the neurological disorders manifested
in clade.
In summary, higher levels of IL-33 and ST2 were observed in
HIV-1 clade B infected cells than in clade C infected cells. The
augmentation in IL-33 affects the expression of important genes
and proteins such as MEF2C. The induction of IL-33 and ST2
also affects neuronal cell functions by inducing apoptosis, as
estimated using caspase-3 assay and inflammatory conditions
and seen as a regulation of innate adaptive immune genes
(NOD2, SLC11A1). Neuropathogenesis in clade B infection is
associated with IL-33/ST2 levels leading to neuroinflammation
and resulting in dysregulation of synaptic function and
apoptosis which are found neuroAIDS.
Figure 5. HIV infection induces apoptosis of CNS cells through the
contribution of IL-33. (A) SKNMC cells were infected with HIV-1
clades B and C. Cytosol extracts were quantified. Caspase-3 activity
was measured using a colorimetric kit from Invitrogen, following
manufacturer instructions (Cat# KHZ0021). Untreated population
was used to define the basal level of apoptotic and dead cells.
(B) SKNMC cells were treated with different IL-33 concentrations for
7 days, following the procedure described above. Untreated population
was used to define the basal level of apoptotic and dead cells. Bar
graph represents the mean ± standard error of percent of mean
fluorescence intensity. Data represents the means ± standard error of
three independent experiments. All the data were analyzed using
GraphPad Prism software. Comparisons between groups were
performed using one-way ANOVA and Tukey’s multiple comparison
post test. Differences were considered significant at p ≤ 0.05.
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
and as a consequence of this, the synaptic strength is favored.
While higher levels can negatively impact long-term potentiation (LTP).20 In addition, low levels of IL-1 help in the
maintenance of short-term plasticity and long-term potentiation
and higher levels damage LTP and depressive-like behavior can
be observed in animal models.20
The results of our study showed a correlation between IL-33
and synaptic plasticity as indicated by obtained inverse effect of
IL-33 and MEF2C after HIV-1 clade B infection (Figure 4).
This suggests a major role of IL-33 in the reduction of MEF2C
and possibly disruption of synaptic plasticity.
Proinflammatory cytokine, such as TNFα and IL-1β,
production is higher in cases of HIV-1 clade B as compared
to clade C.1,32 TNFα and IL-1β induce apoptosis in neurons33
and CNS cells, and their production increases on infection with
HIV-1 clade. In this research, the contribution of IL-33 to
induce apoptosis was assessed (Figure 5B). IL-33 was found to
induce apoptosis as measured by caspase-3 assay. This can be
explained by the ability of IL-33 to activate the production of
other proinflammatory cytokines such as TNFα, IL-1β, IL-6,
and MCP-1 in glial cultures.12,13,34 Therefore, production of IL33 may be implicated in the induction of apoptosis observed in
our results and may be correlated with the clade-specific
neuroAIDS manifestations.
■
METHODS
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
Cell Culture. Primary human astrocytes (HA) were obtained from
Sciencell Laboratories (Cat# 1800; Carlsbad, CA), and the neuronal
cell line, SKNMC cells, was purchased from ATCC (Cat# HTB-10;
Manassas, VA). HA were characterized by immunofluorescent method
using antibody against glial fibrillary acid protein (GFAP). Primary HA
were obtained at passage 2 and used for all experiments between
passages 2 and 8. Cells were cultured as per instructions provided by
the company.
HIV Infection. Cells were infected with HIV-1Ba-L (National
Institutes of Health AIDS Research and Reference Reagent Program;
I
277
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
330
331
332
333
334
335
336
337
338
339
ACS Chemical Neuroscience
Research Article
Table 1. Functional Gene Grouping Included in Human Innate and Adaptive Immune Responses Gene Arraya
functional gene grouping
pattern recognition receptors
cytokines
other genes
Th1 markers/immune response
Th2 markers/immune response
Th17 markers
Treg markers
T cell activation
cytokines
other genes
humoral immunity
inflammatory response
defense response to bacteria
defense response to viruses
a
innate immunity
DDX58 (RIG-I), NLRP3, NOD1 (CARD4), NOD2, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9
(MCP-1), CCL5 (RANTES), CSF2 (GM-CSF), CXCL10, IFNA1, IFNB1, IL18, IL1A, IL1B, IL2, IL8, TNF
APCS, C3, CASP1 (ICE), CD14, CD4, CD40 (TNFRSF5), CD40LG (TNFSF5), CD8A, CRP, HLA-A, HLA-E, IL1R1, IRAK1,
IRF3, IRF7, ITGAM, LY96 (MD-2), LYZ, MAPK1 (ERK2), MAPK8 (JNK1), MBL2, MPO, MX1, MYD88, NFKB1,
NFKBIA (I?Ba/Mad3), STAT1, TICAM1 (TRIF), TRAF6
adaptive immunity
CCR5, CD80, CXCR3, IFNG, IL18, IL23A, SLC11A1, STAT4, TBX21, TLR4, TLR6
CCR4, CCR8, CD86, GATA3, IFNB1, IL10, IL13, IL18, IL4, IL5, IL6, NOD2, STAT6
CCR6, IL17A, RORC, STAT3
CCR4, CCR8, FOXP3, IL10
CD80, CD86, ICAM1, IFNG, IL23A, IL6, SLC11A1
CCL2 (MCP-1), CCL5 (RANTES), CSF2 (GM-CSF), CXCL10 (INP10), IFNA1, IFNG, IL10, IL13, IL17A, IL18, IL2, IL23A,
IL4, IL5, IL6, IL8, TNF
CD4, CD40 (TNFRSF5), CD40LG (TNFSF5), CD8A, CRP, FASLG (TNFSF6), HLA-A, IFNAR1, IFNGR1, IL1B, IL1R1,
IRF3, IRF7, ITGAM, JAK2, MAPK8 (JNK1), MBL2, MX1, NFKB1, RAG1, STAT1
C3, CCL2 (MCP-1), CCR6, CRP, IFNB1, IFNG, IL6, MBL2, NOD2, TNF.
APCS, C3, CCL5 (RANTES), CRP, FOXP3, IL1A, IL1B, IL4, IL6, MBL2, STAT3, TNF
IFNB1, IFNG, IL23A, IL6, LYZ, MBL2, MYD88, NOD1 (CARD4), NOD2, SLC11A1, TLR1, TLR3, TLR4, TLR6, TLR9, TNF
CD4, CD40 (TNFRSF5), CD86, CD8A, CXCL10 (INP10), DDX58 (RIG-I), HLA-A, IFNAR1, IFNB1, IL23A, IL6, IRF3,
NLRP3, TICAM1 (TRIF), TLR3, TLR7, TLR8, TYK2
This table shows the list of functional genes. Highlighted are genes regulated by treatment with 2 ng of human recombinant IL-33.
Table 2. IL-33 Induces Immune Response Activation in CNS Cells: Fold-up and Fold-down Changesa
abbreviation
fold-up
change
name
CSF2
colony stimulating factor 2 (granulocyte macrophage)
+2.31
MX1
myxovirus (influenza virus) resistance 1, infection-inducible protein p78 (mouse)
+2.03
NOD2*
nucleotide-binding oligomerization domain containing 2
+6.63
RAG
recombination activation gene 1
+2.85
SLC11A1* Solute carrier family 11 (protein coupled divalent metal ion transporters) member 1
+3.97
TLR7
toll-like receptor 7
+2.38
abbreviation
name
fold-down change
CXCR3
TLR2
TLR9
chemokine (C-X-C motif) receptor 3
Toll-like receptor 2
toll-like receptor 9
−2.71
−2.69
−2.06
function
cytokine
innate other genes
protein recognition receptor humoral immunity
adaptive response
T cell activation
pattern recognition receptor defense to virus
function
Th marker
pattern recognition receptor
pattern recognition receptor
a
SKNMC cells were treated with 2 ng of human recombinant IL-33 for 7 days. Cells were collected, RNAs were extracted, and human innate and
adaptive immune responses gene array was done using 96-well format. This array interrogates 84 genes related to the innate and adaptive immune
response.
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
Cat# 510) and HIV-1 98CN006 (National Institutes of Health AIDS
Research and Reference Reagent Program; Cat# 4164). First, the
viruses were propagated using standard protocol. The supernatants
were further collected and assayed with p24 ELISA Zeptometrix (Cat#
NC9130878) to determine the concentration of p24 protein secreted
in the supernatant during 15 days. The collected supernatants were
used as a source and stoke of HIV viruses.
HA and SKNMC cells were infected separately at different p24
starting concentrations for HIV-1 clades B and C overnight with
previous Polybrene activation for 8 h. Media was removed, and cells
were washed extensively to eliminate the unbound virus before addition of fresh medium. After adding fresh media, aliquots were collected. On alternate days, the cultures were supplemented with fresh
media. On day 7 postinfection, the supernatants were collected
and tested with p24 ELISA Zeptometrix (Cat# NC9130878). The p24
concentration obtained from day zero were compared with aliquots
collected at 7 day postinfection to know the increment of p24. The
initial amount of p24 selected for future infections was the one that
produced a similar level of infection between clades, considered
as concentration of p24. The standardization experiments were
performed in triplicate with the same batch of viruses and a similar
number of passages of cells (Figure 1). The selected concentrations of
p24 were 100 and 200 ng for further experiments for clades B and C,
respectively. The infection was confirmed and significant when obtained differences were more than double as the initial p24 at day zero.
ELISA. Concentration of HIV-1 p24 antigen in HIV-infected cell
culture supernatants was determined using the Retro-tek HIV-1 p24
antigen ELISA kit (Cat# 0801111; Zeptometrix, Buffalo, NY).
IL-33 and ST2 secreted levels were also detected using commercially
available human IL-33 DuoSet (Cat#DY3625) and human ST2/IL-1
R4 DuoSet (Cat#DY523, R&D systems, Minneapolis, MN) ELISA
kits. Protocols for each ELISA were followed according to the
manufacturer’s instructions.
Quantitative Real Time PCR (qRT-PCR). Gene expression was
quantitated using real time qRT-PCR method. Total RNA from HA
and SKNMC obtained after 7 days of HIV 1 clade infection (100 ng of
clade B and 200 ng of clade C) was used to study IL-33, ST2, and
MEF2C gene expression. Taqman assays for IL-33 (Hs01125942_m1;
Applied Biosystems, CA), ST2 (Hs00545033_m1; Applied Biosystems, CA), MEF2C (assay ID Hs00231149_m1; Applied Biosystems,
CA), and GAPDH (Hs99999905_m1) were used.
Western Blot (WB). IL-33 and ST2 protein levels were tested
using WB analysis. The cells were infected with 100 ng of clade B and
200 ng of clade C. After 7 days, the cells were harvested and the cell
J
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
ACS Chemical Neuroscience
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
Research Article
lysates were prepared in protein extraction reagent (Pierce
Biotechnology, Rockford, IL) containing protease inhibitor (Pierce
Biotechnology) following the manufacturer’s recommendations.41 The
protein levels were quantified using the protein assay reagent (Bio-Rad
Laboratories, Hercules, CA). Equal quantities of protein (50 μg) were
denatured, subjected to SDS-PAGE, transferred into a nitrocellulose
membrane (Bio-Rad Laboratories), blocked with 10% nonfat dry milk,
washed with Tris-buffered saline/Tween 20, and incubated overnight
with primary antibodies against IL-33 or ST2 (Cat# SAB3500439
and PRS3363, respectively; Sigma-Aldrich). After overnight incubation,
the membranes were washed and incubated for 1 h with secondary
antibody, horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG antibody (Millipore). The WB was developed using the Super
Signal West Pico chemiluminescent substrate (Pierce Biotechnology).
Primary goat anti-MEF2C and secondary donkey anti-goat HRP (Cat#
sc-13266 and sc-2020; Santa Cruz) were used for the detection of
MEF2C protein expression after HIV infection.
Flow Cytometry. HA and SKNMC cells were infected with HIV-1
clades B and C as described above. Golgi inhibitor was used for the
cases of determination of IL-33 and ST2. Cells were harvested
according to manufacturer’s recommendations (Sciencell) using
trypsin-EDTA to detach cells and pipeting accordingly to break cell
clumps. After cells were counted using a TC20 automated cell counter
(Biorad), cells were distributed accordingly and blocked for 10 min on
ice using inactivated serum from the species in which the secondary
antibody was made. In addition, human inactivated serum was used as
a blocker, too. Cell pellets were fixed and permeabilized with Cytofix/
Cytoperm solution (BD Bioscience, San Jose, CA), and then they were
incubated with primary antibody for 30 min, followed by washing
three times and then staining with secondary antibody.
Primary rabbit anti-IL-33 (Cat# SAB3500439; Sigma-Aldrich) or
rabbit anti-ST2 (Cat# PRS3363; Sigma-Aldrich) followed by
secondary goat anti-rabbit IgG-FITC (Cat# AP132F; Millipore)
were used for the staining of IL-33 and its receptor. For flow
cytometry experiments, SKNMC cells were treated with different
IL-33 concentrations for 24 h, and intracellular levels of MEF2C were
detected using goat anti-human MEF2C as a primary antibody and
donkey anti-goat FITC as secondary antibody (Cat# sc-13266
and sc2024, respectively; Santa Cruz). Cells were gated based on
unlabeled and secondary controls. Cells were acquired using an Accuri
Cytometer instrument (Ann Arbor, MI) and analyzed using FlowJo
software (FlowJo v9; Ashland, OR). In order to assess cell doublets
(clumping) and discriminate them, the provider recommended the
plotting of FSC-A against FSC-H. Signals from single cells in the flow
cell pass through the laser beam, and FSC-A vs FSC-H signals
correlate linearly 2. Data shows that cell clumps were not visible during
the experiments.
Caspase-3 Activity Assay. Caspase-3 activity was measured in
lysates from HIV-infected SK-N-MC cells using a colorimetric assay
(Cat# KHZ0021; Invitrogen). Camptothecin was used as a positive
control (Sigma-Aldrich; Cat# C9911). SKNMC cells were infected
with HIV-1 clade B (100 ug) and clade C (200 ug) following protocols
described above. Separately, SKNMC cells were treated with different
IL-33 concentrations for 7 days (120, 240, and 480 pg/mL; 1 and
2 ng/mL). All the cells were harvested and lysed, and caspase-3 activity
was quantitated in the cell lysates. Caspase-3 activity in samples was
read at 400 or 405 nm in a microplate reader (Synergy HT, Biotek).
RT2 Profiler PCR Array Human Innate and Adaptive Immune
Responses. SKNMC cells were treated with 2 ng of human
recombinant IL-33 (Cat# 3625-IL-010; R&D systems, Minneapolis,
MN) during 7 days and harvested. The pellets were used for the
mRNA isolation using the Illustra triplePrep kit (GE Healthcare Life
Sciences, U.K.; Cat# 28-9425-44), and on-column DNase treatment
step was also performed in the procedure. RNA was measured via
microspot RNA reader (Synergy HT Multi-Mode Microplate Reader
from BioTek). A total of 1 μg of RNA was used for the first strand
cDNA synthesis using SA Biosciences’s RT2 First Strand kit (Cat#
330401) as per the supplier’s protocol. Genomic DNA elimination
step was performed before proceeding with reverse transcription.
Human innate and adaptive immune responses was done using
96-well format (Qiagen; Cat# PAHS-052Z) using the Stratagene
Mx3000p qRT-PCR instrument. This array interrogates 84 genes
related to the innate and adaptive response. Innate immunity includes
pattern recognition, cytokines, as well as other genes involved in the
innate response, while adaptive immunity includes Th1, Th2, Th17,
Treg markers/immune response, T cell activation, humoral immunity,
inflammatory response, and defense response to bacteria and viruses.
Functional grouping genes are shown in Table 1. Relative abundance
of each mRNA species was assessed using RT2 SYBR Green/ROX
PCR Master mix (SABiosciences, Cat# 330520), used for the real-time
PCR arrays. The real time PCR cycling program (as indicated by the
manufacturer) was run on a Stratagene Mx3000p qRT-PCR instrument. Ct data were analyzed in the data analysis template on the
manufacturer’s Web site (http://pcrdataanalysis.sabiosciences.com/
pcr/arrayanalysis.php). Controls are also included in each array for
genomic DNA contamination, RNA quality, and general PCR performance.
Statistics. Experiments were performed at least three times in
duplicate unless otherwise indicated in the figure legend. The values
obtained were averaged, and data are represented as the mean +
standard error. All the data were analyzed using GraphPad Prism
software. Comparisons between groups were performed using one-way
ANOVA and Tukey’s multiple comparison post test. Differences were
considered significant at p ≤ 0.05.
■
AUTHOR INFORMATION
477
Corresponding Author
478
*E-mail: nairm@fiu.edu. Telephone: 305-348-1493. Fax: 305348-1109.
479
Author Contributions
481
Conceived and designed the experiments: A.Y., M.A., and M.N.
Performed the experiments: A.Y. and A.K.. Analyzed the data:
A.Y., M.A., A.R., V.S.A., and K.M.C. Contributed reagents/materials/
analysis tools: A.K., M.A., and M.N. Wrote the paper: A.Y.
482
Funding
486
The present study was supported by grants from the National
Institutes of Health (NIH): 1R01MH085259, 1R01DA027049,
5R01DA021537, and 1RO37DA025576.
487
Notes
490
The authors declare no competing financial interest.
491
ABBREVIATIONS
Cat#, catalog number; CNS, central nervous system; CSF2,
colony stimulating factor 2; DNA, deoxyribonucleic acid; ELISA,
enzyme-linked immunosorbent assay; ERK1/2, extracellularsignal-regulated kinase 1/2; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GFAP, glial fibrillary acid protein;
HA, human astrocytes; HAND, HIV associated neurocognitive
disorders; HIV-1, human immunodeficiency virus; HRP,
horseradish peroxidase; IgG-FITC, fluorescein isothiocyanate;
IL-1β, interleukin-1 beta; IL-33, interleukin 33; IL-6, interleukin
6; MAP, mitogen-activated protein kinase; MCP-1, monocyte
chemotactic protein 1; M-CSF, macrophage colony-stimulating
factor; MEF2C, myocyte enhancer factor 2C; MX1, myxovirus
(influenza virus) resistance 1; NF-κB, nuclear factor of kappa
light polypeptide gene enhancer in B-cells; NOD2, nucleotidebinding oligomerization domain containing 2; P24, capsid
protein; p38 MAPK, P38 mitogen-activated protein kinases;
pg/mL, pico gram per milliliters; qRT-PCR, real-time
quantitative reverse transcription PCR; RAG1, recombination
activation gene 1; RNA, ribonucleic acid; SDS-PAGE,
polyacrylamide gel electrophoresis; SKNMC, brain cell line;
SLC11A1, solute carrier family 11; ST2, suppression of
tumorigenicity 2/Interleukin 1 receptor-like 1; TAI, transcript
492
■
K
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
480
483
484
485
488
489
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
ACS Chemical Neuroscience
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
Research Article
in HIV-associated neurocognitive disorders (HAND). PLoS One 8 (4),
e61399.
(16) Albensi, B. C., and Mattson, M. P. (2000) Evidence for the
involvement of TNF and NF-kappaB in hippocampal synaptic
plasticity. Synapse 35 (2), 151−159.
(17) Barrientos, R. M., O'Reilly, R. C., and Rudy, J. W. (2002)
Memory for context is impaired by injecting anisomycin into dorsal
hippocampus following context exploration. Behav. Brain Res. 134 (1−
2), 299−306.
(18) Di Filippo, M., Chiasserini, D., Gardoni, F., Viviani, B., Tozzi, A.,
Giampa, C., Costa, C., Tantucci, M., Zianni, E., Boraso, M., Siliquini,
S., de Iure, A., Ghiglieri, V., Colcelli, E., Baker, D., Sarchielli, P., Fusco,
F. R., Di Luca, M., and Calabresi, P. (2013) Effects of central and
peripheral inflammation on hippocampal synaptic plasticity. Neurobiol.
Dis. 52, 229−36.
(19) Di Filippo, M., Sarchielli, P., Picconi, B., and Calabresi, P.
(2008) Neuroinflammation and synaptic plasticity: theoretical basis for
a novel, immune-centred, therapeutic approach to neurological
disorders. Trends Pharmacol. Sci. 29 (8), 402−12.
(20) Khairova, R. A., Machado-Vieira, R., Du, J., and Manji, H. K.
(2009) A potential role for pro-inflammatory cytokines in regulating
synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 12 (4), 561−78.
(21) Kim, Y. K., Na, K. S., Shin, K. H., Jung, H. Y., Choi, S. H., and
Kim, J. B. (2007) Cytokine imbalance in the pathophysiology of major
depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31
(5), 1044−53.
(22) Rao, V. R., Sas, A. R., Eugenin, E. A., Siddappa, N. B., BimonteNelson, H., Berman, J. W., Ranga, U., Tyor, W. R., and Prasad, V. R.
(2008) HIV-1 clade-specific differences in the induction of neuropathogenesis. J. Neurosci. 28 (40), 10010−6.
(23) White, D. A., Heaton, R. K., and Monsch, A. U. (1995)
Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV
Neurobehavioral Research Center. J. Int. Neuropsychol. Soc. 1 (3),
304−15.
(24) Tyor, W., Fritz-French, C., and Nath, A. (2013) Effect of HIV
clade differences on the onset and severity of HIV-associated
neurocognitive disorders. J. NeuroVirol. 19 (6), 515−22.
(25) Tajima, S., Oshikawa, K., Tominaga, S.-i., and Sugiyama, Y.
(2003) THe increase in serum soluble st2 protein upon acute
exacerbation of idiopathic pulmonary fibrosis*. Chest 124 (4), 1206−
1214.
(26) Akhtar, M. W., Kim, M. S., Adachi, M., Morris, M. J., Qi, X.,
Richardson, J. A., Bassel-Duby, R., Olson, E. N., Kavalali, E. T., and
Monteggia, L. M. (2012) In vivo analysis of MEF2 transcription
factors in synapse regulation and neuronal survival. PLoS One 7 (4),
e34863.
(27) Li, H., Radford, J. C., Ragusa, M. J., Shea, K. L., McKercher, S.
R., Zaremba, J. D., Soussou, W., Nie, Z., Kang, Y. J., Nakanishi, N.,
Okamoto, S., Roberts, A. J., Schwarz, J. J., and Lipton, S. A. (2008)
Transcription factor MEF2C influences neural stem/progenitor cell
differentiation and maturation in vivo. Proc. Natl. Acad. Sci. U. S. A. 105
(27), 9397−402.
(28) Miyagaki, T., Sugaya, M., Yokobayashi, H., Kato, T., Ohmatsu,
H., Fujita, H., Saeki, H., Kikuchi, Y., Tamaki, T., and Sato, S. (2011)
High levels of soluble ST2 and low levels of IL-33 in sera of patients
with HIV infection. J. Invest. Dermatol. 131 (3), 794−6.
(29) Lu, J., McKinsey, T. A., Nicol, R. L., and Olson, E. N. (2000)
Signal-dependent activation of the MEF2 transcription factor by
dissociation from histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 97
(8), 4070−4075.
(30) Xu, Z., Yoshida, T., Wu, L., Maiti, D., Cebotaru, L., and Duh, E.
J. (2014) Transcription Factor MEF2C Suppresses Endothelial Cell
̂ and KLF2. J. Cell. Physiol.
Inflammation via Regulation of NF†I°B
230, 1310.
(31) Yin, Y., She, H., Li, W., Yang, Q., Guo, S., and Mao, Z. (2012)
Modulation of neuronal survival factor MEF2 by kinases in
Parkinsonâ€s disease. Front. Physiol. 3, 171.
accumulation index; TLR7, toll-like receptor 7; TNFα, tumor
necrosis factor alpha; WB, Western blot
■
REFERENCES
(1) Gandhi, N., Saiyed, Z., Thangavel, S., Rodriguez, J., Rao, K. V.,
and Nair, M. P. (2009) Differential effects of HIV type 1 clade B and
clade C Tat protein on expression of proinflammatory and
antiinflammatory cytokines by primary monocytes. AIDS Res. Hum.
Retroviruses 25 (7), 691−9.
(2) Samikkannu, T., Rao, K. V., Kanthikeel, S. P., Atluri, V. S. R.,
Agudelo, M., Roy, U., and Nair, M. P. (2014) Immunoneuropathogenesis of HIV-1 clades B and C: Role of redox expression and thiol
modification. Free Radical Biol. Med. 69, 136−144.
(3) Riedel, D., Ghate, M., Nene, M., Paranjape, R., Mehendale, S.,
Bollinger, R., Sacktor, N., McArthur, J., and Nath, A. (2006) Screening
for human immunodeficiency virus (HIV) dementia in an HIV clade
C-infected population in India. J. NeuroVirol. 12 (1), 34−8.
(4) Satishchandra, P., Nalini, A., Gourie-Devi, M., Khanna, N.,
Santosh, V., Ravi, V., Desai, A., Chandramuki, A., Jayakumar, P. N., and
Shankar, S. K. (2000) Profile of neurologic disorders associated with
HIV/AIDS from Bangalore, south India (1989−96). Indian J. Med. Res.
111, 14−23.
(5) Abecasis, A., Wensing, A., Paraskevis, D., Vercauteren, J., Theys,
K., Van de Vijver, D., Albert, J., Asjo, B., Balotta, C., Beshkov, D.,
Camacho, R., Clotet, B., De Gascun, C., Griskevicius, A., Grossman, Z.,
Hamouda, O., Horban, A., Kolupajeva, T., Korn, K., Kostrikis, L.,
Kucherer, C., Liitsola, K., Linka, M., Nielsen, C., Otelea, D., Paredes,
R., Poljak, M., Puchhammer-Stockl, E., Schmit, J.-C., Sonnerborg, A.,
Stanekova, D., Stanojevic, M., Struck, D., Boucher, C., and Vandamme,
A.-M. (2013) HIV-1 subtype distribution and its demographic
determinants in newly diagnosed patients in Europe suggest highly
compartmentalized epidemics. Retrovirology 10 (1), 7.
(6) Power, C., Gill, M. J., and Johnson, R. T. (2002) Progress in
clinical neurosciences: The neuropathogenesis of HIV infection: hostvirus interaction and the impact of therapy. Can. J. Neurol. Sci. 29 (1),
19−32.
(7) Carriere, V., Roussel, L., Ortega, N., Lacorre, D. A., Americh, L.,
Aguilar, L., Bouche, G., and Girard, J. P. (2007) IL-33, the IL-1-like
cytokine ligand for ST2 receptor, is a chromatin-associated nuclear
factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 104 (1), 282−7.
(8) Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E.,
McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X.,
Gorman, D. M., Bazan, J. F., and Kastelein, R. A. (2005) IL-33, an
Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related
Protein ST2 and Induces T Helper Type 2-Associated Cytokines.
Immunity 23 (5), 479−490.
(9) Le Goffic, R., Arshad, M. I., Rauch, M., L'Helgoualc'h, A., Delmas,
B., Piquet-Pellorce, C., and Samson, M. (2011) Infection with
influenza virus induces IL-33 in murine lungs. Am. J. Respir. Cell
Mol. Biol. 45 (6), 1125−1132.
(10) Hayakawa, H., Hayakawa, M., Kume, A., and Tominaga, S.
(2007) Soluble ST2 blocks interleukin-33 signaling in allergic airway
inflammation. J. Biol. Chem. 282 (36), 26369−80.
(11) Miller, A. (2011) Role of IL-33 in inflammation and disease. J.
Inflammation 8 (1), 22.
(12) Hudson, C. A., Christophi, G. P., Gruber, R. C., Wilmore, J. R.,
Lawrence, D. A., and Massa, P. T. (2008) Induction of IL-33
expression and activity in central nervous system glia. J. Leukocyte Biol.
84 (3), 631−43.
(13) Yasuoka, S., Kawanokuchi, J., Parajuli, B., Jin, S., Doi, Y., Noda,
M., Sonobe, Y., Takeuchi, H., Mizuno, T., and Suzumura, A. (2011)
Production and functions of IL-33 in the central nervous system. Brain
Res. 1385, 8−17.
(14) Smith, J. A., Das, A., Ray, S. K., and Banik, N. L. (2012) Role of
pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res. Bull. 87 (1), 10−20.
(15) Atluri, V. S., Kanthikeel, S. P., Reddy, P. V., Yndart, A., and Nair,
M. P. (2013) Human synaptic plasticity gene expression profile and
dendritic spine density changes in HIV-infected human CNS cells: role
L
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
ACS Chemical Neuroscience
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
Research Article
(32) McNamee, J. P., Bellier, P. V., Kutzner, B. C., and Wilkins, R. C.
(2005) Effect of pro-inflammatory cytokines on spontaneous
apoptosis in leukocyte sub-sets within a whole blood culture.
Cytokine+ 31 (2), 161−167.
(33) Alvarez, S., Blanco, A., Fresno, M., and Munoz-Fernandez, M. A.
(2011) TNF-alpha contributes to caspase-3 independent apoptosis in
neuroblastoma cells: role of NFAT. PLoS One 6 (1), e16100.
(34) Ohagen, A., Ghosh, S., He, J., Huang, K., Chen, Y., Yuan, M.,
Osathanondh, R., Gartner, S., Shi, B., Shaw, G., and Gabuzda, D.
(1999) Apoptosis induced by infection of primary brain cultures with
diverse human immunodeficiency virus type 1 isolates: evidence for a
role of the envelope. J. Virol 73 (2), 897−906.
(35) Tamrakar, A. K., Schertzer, J. D., Chiu, T. T., Foley, K. P., Bilan,
P. J., Philpott, D. J., and Klip, A. (2010) NOD2 activation induces
muscle cell-autonomous innate immune responses and insulin
resistance. Endocrinology 151 (12), 5624−37.
(36) Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., and
Nunez, G. (2001) Nod2, a Nod1/Apaf-1 Family Member That Is
Restricted to Monocytes and Activates NF-kB. J. Biol. Chem. 276 (7),
4812−4818.
(37) Pitha, P. M. (2011) Innate antiviral response: role in HIV-1
infection. Viruses 3 (7), 1179−203.
(38) Stroud, J. C., Oltman, A., Han, A., Bates, D. L., and Chen, L.
(2009) Structural Basis of HIV-1 Activation by NF-I°̂ B—A HigherOrder Complex of p50: RelA Bound to the HIV-1 LTR. J. Mol. Biol.
393 (1), 98−112.
(39) Feng, Y., and Cohen, S. N. (2013) Upregulation of the host
SLC11A1 gene by Clostridium difficile toxin B facilitates glucosylation
of Rho GTPases and enhances toxin lethality. Infect. Immun. 81 (8),
2724−32.
(40) Awomoyi, A. A. (2007) The human solute carrier family 11
member 1 protein (SLC11A1): linking infections, autoimmunity and
cancer? FEMS Immunol. Med. Microbiol. 49 (3), 324−9.
(41) Agudelo, M., Gandhi, N., Saiyed, Z., Pichili, V., Thangavel, S.,
Khatavkar, P., Yndart-Arias, A., and Nair, M. (2011) Effects of alcohol
on histone deacetylase 2 (HDAC2) and the neuroprotective role of
trichostatin A (TSA). Alcohol.: Clin. Exp. Res. 35 (8), 1550−1556.
M
DOI: 10.1021/acschemneuro.5b00156
ACS Chem. Neurosci. XXXX, XXX, XXX−XXX